Patents by Inventor Eric Chea
Eric Chea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230219991Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 8, 2023Publication date: July 13, 2023Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20230131867Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: September 19, 2022Publication date: April 27, 2023Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
-
Patent number: 11447515Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: June 16, 2017Date of Patent: September 20, 2022Assignee: SLOAN KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan
-
Patent number: 10906926Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: GrantFiled: March 23, 2020Date of Patent: February 2, 2021Assignees: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCERInventors: David Y. Gin, Eric Chea, Alberto Fernandez-Tejada, Jeffrey Gardner, Jason Lewis, Philip Livingston, J. Tyler Martin, Lars Nordstroem, Naga Vara Kishore Pillarsetty, Govind Ragupathi, Derek Tan
-
Publication number: 20210002316Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: August 27, 2020Publication date: January 7, 2021Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN, Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20200239509Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: March 23, 2020Publication date: July 30, 2020Applicants: ADJUVANCE TECHNOLOGIES, INC., MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20180327436Abstract: The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.Type: ApplicationFiled: November 4, 2016Publication date: November 15, 2018Applicant: ADJUVANCE TECHNOLOGIES, INC.Inventors: David Y. GIN (Deceased), Eric CHEA, Alberto FERNANDEZ-TEJADA, Jeffrey GARDNER, Jason LEWIS, Philip LIVINGSTON, J. Tyler MARTIN, Lars NORDSTROEM, Naga Vara Kishore PILLARSETTY, Govind RAGUPATHI, Derek TAN
-
Publication number: 20170283450Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: David GIN, Michelle ADAMS, Kai DENG, Philip LIVINGSTON, Govindaswami RAGUPATHI, Eric CHEA, Alberto FERNANDEZ-TEJADA, Lars Ulrik NORDSTROEM, William WALKOWICZ, Jeffrey GARDNER, Derek TAN
-
Patent number: 9718850Abstract: The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. QS-7 is a potent immuno-adjuvant that is significantly less toxic than QS-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines. Tedious isolation and purification protocols have hindered the clinical development of QS-7. A novel semi-synthetic method is provided wherein a hydrolyzed prosapogenin mixture is used to synthesize QS-7, QS-21, and related analogs, greatly facilitating access to QS-7 and QS-21 analogs for preclinical and clinical evaluation.Type: GrantFiled: September 24, 2014Date of Patent: August 1, 2017Assignee: MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: David Gin, Michelle Adams, Kai Deng, Philip Livingston, Govindaswami Ragupathi, Eric Chea, Alberto Fernandez-Tejada, Lars Ulrik Nordstroem, William Walkowicz, Jeffrey Gardner, Derek Tan